Traws Pharma, Inc. (TRAW) SEC filings

TRAWNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30

$0.25−0.03 (-11.87%)

Close on Nov 13, 2026Market cap $3.86MP/E –Yield –

SEC filings

40 of Traws Pharma's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Oct 23, 2026	Oct 23, 2026	SEC EDGAR
Proxy statement	DEF 14A	Dec 3, 2026	Oct 20, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Jul 29, 2026	Jul 31, 2026	SEC EDGAR
Current report	8-K	Jul 10, 2026	Jul 10, 2026	SEC EDGAR
Current report	8-K	Jul 8, 2026	Jul 9, 2026	SEC EDGAR
Current report	8-K	Jun 22, 2026	Jun 22, 2026	SEC EDGAR
Current report	8-K	Jun 12, 2026	Jun 12, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jul 8, 2026	May 29, 2026	SEC EDGAR
Current report	8-K	May 27, 2026	May 27, 2026	SEC EDGAR
Current report	8-K	May 22, 2026	May 26, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 15, 2026	SEC EDGAR
Current report	8-K	May 15, 2026	May 15, 2026	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2025	Apr 30, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Apr 15, 2026	SEC EDGAR
Current report	8-K	Apr 15, 2026	Apr 15, 2026	SEC EDGAR
Current report	8-K	Apr 15, 2026	Apr 15, 2026	SEC EDGAR
Current report	8-K	Feb 19, 2026	Feb 19, 2026	SEC EDGAR
Current report	8-K	Jan 26, 2026	Jan 26, 2026	SEC EDGAR
Current report	8-K	Jan 13, 2026	Jan 13, 2026	SEC EDGAR
Current report	8-K	Dec 17, 2025	Dec 17, 2025	SEC EDGAR
Current report	8-K	Dec 12, 2025	Dec 16, 2025	SEC EDGAR
Current report	8-K	Nov 21, 2025	Nov 28, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Oct 12, 2025	Oct 17, 2025	SEC EDGAR
Current report	8-K	Oct 14, 2025	Oct 14, 2025	SEC EDGAR
Proxy statement	DEF 14A	Nov 21, 2025	Oct 8, 2025	SEC EDGAR
Current report	8-K	Oct 1, 2025	Oct 6, 2025	SEC EDGAR
Current report	8-K	Sep 9, 2025	Sep 12, 2025	SEC EDGAR
Current report	8-K	Aug 18, 2025	Aug 18, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Aug 14, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Jul 2, 2025	Jul 3, 2025	SEC EDGAR
Current report	8-K	Jun 30, 2025	Jun 30, 2025	SEC EDGAR
Current report	8-K	Jun 3, 2025	Jun 3, 2025	SEC EDGAR
Current report	8-K	May 27, 2025	May 27, 2025	SEC EDGAR
Current report	8-K	May 19, 2025	May 19, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Traws Pharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Sep 23, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TRAW.

Compare: TRAW vs TVRD · TRAW vs CNTB · TRAW vs UPB · TRAW vs XBIO · TRAW vs IMNM

Revenue growth1134.5% · median 3.0%

Operating margin-772.2% · median -4166.2%

Net margin-773.0% · median -3965.1%

Company	Revenue	Growth
IMNM	$4.02M	-63.3%
XBIO	$2.96M	+3.5%
CNTB	$2.95M	+50.3%
UPB	$2.87M	+2.5%
TRAW	$2.79M	+1134.5%
TVRD	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 7
Held by institutions: 40.1%
Auditor: KPMG LLP
SEC CIK: 1130598

Advertisement
300 × 250

See a number that looks wrong?